HSBC Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Posted by Stanley Muller on Sep 10th, 2026

Merck & Co., Inc. (NYSE:MRK – Get Free Report) had its price target increased by analysts at HSBC from $150.00 to $172.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. HSBC’s price objective would suggest a potential upside of 17.47% from the stock’s current price.

Several other research firms also recently commented on MRK. Weiss Ratings upgraded Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Cantor Fitzgerald restated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. Argus raised their price target on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. UBS Group raised their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Finally, CICC Research initiated coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price target on the stock. Seventeen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus target price of $151.32.

Read Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Trading Down 0.8%

Shares of MRK opened at $146.42 on Thursday. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $156.92. The firm has a market cap of $361.25 billion, a price-to-earnings ratio of 117.17, a PEG ratio of 6.46 and a beta of 0.21. The firm has a 50 day moving average price of $135.91 and a 200-day moving average price of $124.10. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Insider Activity

In other news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares of the company’s stock, valued at $4,942,755. This represents a 21.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Several hedge funds have recently added to or reduced their stakes in MRK. Brighton Jones LLC increased its holdings in shares of Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in Merck & Co., Inc. by 52.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after purchasing an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC grew its position in Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after purchasing an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC grew its position in Merck & Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after purchasing an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Merck & Co., Inc. by 111.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after purchasing an additional 359,356 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.